Trial Profile
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms LAPTOP
- 01 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine.
- 26 Sep 2023 Planned End Date changed from 1 May 2024 to 1 Jun 2024.
- 26 Sep 2023 Planned primary completion date changed from 1 May 2024 to 1 Jun 2024.